Phase II Clinical Trial (HALT MS: Immune Tolerance Network) of High Dose Immunosuppressive Therapy (HDIT) and Autologous Hematopoetic Stem Cell Transplantation (AHSCT) for Active Relapsing-Remitting (RR) Multiple Sclerosis (MS): Early Results

George H. Kraft, MD, MS, Seattle; James D. Bowen, MD, Kirkland; Harry Openshaw, MD, Duarte; Stephen J. Forman MD, Duarte; Elliot M. Frohman, MD, Dallas; Linda M. Griffith, MD, Bethesda; George J. Hutton, MD, Houston; Paolo A. Muraro, MD, London; Uday Popat, MD, Houston; Michael K. Racke, MD, Columbus; Peter Sayre, MD, San Francisco; Olaf Stuve, MD, Dallas; Annette Wundes, MD, Seattle; Richard A. Nash, MD, Seattle.

Objective

To determine if HDIT/AHSCT induces sustained remissions and prevents loss of neurological function in poorly-responsive RRMS.

Background

HDIT/AHSCT may induce sustained remissions in patients with autoimmune disease. In a previous clinical trial of HDIT/AHSCT for advanced progressive-type MS (median EDSS 7.0), estimated progression rate was 37% at 6 years. Since degenerative changes may contribute to loss of neurological function in progressive-type MS, HDIT/AHSCT in RRMS was studied.

Design/Methods

- Phase II clinical trial of HDIT/AHSCT with high-dose chemotherapy (BEAM) and antithymocyte globulin was conducted in RRMS (EDSS 3.0-5.5 with ≥ 2 relapses on treatment and ≥ 1.0 EDSS worsening over past year).
- Autologous hematopoietic cell graft was T-cell depleted by CD34 selection.
- Sample size was 25 patients with planned 5-year follow-up consisting of 8 required study visits
- Case reports of first three patients are presented.

Halt-MS Inclusion Criteria*

- Relapsing remitting MS with cumulative disability, or progressive relapsing MS
- Duration of MS less than 15 years from diagnosis
- EDSS 3.0-5.5 (functional system changes in cerebral/mental functions and in bowel and bladder functions not taken into consideration in determining EDSS for protocol eligibility)
- T2 abnormalities on brain MRI consistent with MS
- Two or more relapses in 12 months or less on IFN or GA, or cytotoxic therapy with EDSS increase > 0.5 maintained for > 4 weeks OR
- at least three gadolinium-enhancing lesions on MRI, obtained 3-4 months after relapse
- Currently in the process of being modified

Case 1

- 27 yo RRMS Diagnosed: 1999
- Previous treatment: Weekly IFNβ1a, bx IFNβ1a, IFNβ1b, GA, methotrexate, mitoxantrone, iv methylprednisolone, plasmapheresis
- Transplant: 2/2007
- EDSS: 9/2000 – when screened: 5.5
  2/2008 1 year S/P: 4.5
  No exacerbations; MRI = no enhancement
  Now off all MS medication

Case 2

- 26 yo female RRMS Diagnosed: 2004
- Previous treatment: GA, IV methylprednisolone
- EDSS:
  10/2006 – when screened: 4.5
  1/2008 6mo S/P: 2.0
  No exacerbations; MRI = no enhancement
  Now off all MS medication

Case 3

- 46 yo RRMS Diagnosed: 2003
- Previous treatment: GA, mitoxantrone
- EDSS:
  2/2008 7mo S/P: 4.5*
  No exacerbations
  Now off all MS medication
- Complicated by low back pain and HNP

Referring Information:

Duarte, CA (City of Hope): 626-256-467
Dallas, TX (UT Southwestern): 214-645-0560
Houston, TX (MD Anderson): 713-794-162
Houston, TX (Baylor College of Med): 713-798-6097
Seattle, WA (Fred Hutchinson): 206-667-4916

References:


Supported by the National Institutes of Health and the Immune Tolerance Network

Website: halt-ms.org

Presented at the American Academy of Neurology 60th Annual Meeting, 2008

Contact information: ghkraft@uwashington.edu